

PROBIOTICS RESOURCE CENTER

Theater Schedule

Speakers Bio & Abstract

DAY 1

Wednesday November 2, 2022

1:50–2:30

Cinzia Randazzo, Ph.D.

Associate Professor at University of Catania; CEO of Probioetna srl.



Bio

Associate professor at the University of Catania, Italy since 2014, she is co-founder of ProBioEtna, a research-based company of University of Catania. She has a broad microbiology science background. Her current research activity focuses on the development of probiotics for human health, primarily based on the discovery of novel functional strains to restore and maintain women's well-being.

Company

CSL USA INC. (Cultures Supporting Life), offers technology solutions and capacity to meet the growing needs of the US biotechnology market. CSL USA's fermentation facility, located in Franksville, Wisconsin will support the growing Food, Beverage, Health, and Nutrition markets. CSL USA has full access to strains and technologies developed by Sacco System (Milan, Italy) over its 150 years of history.

Sacco System produces food ingredients including food cultures, bacterial cultures, and probiotics, for the dairy, food, dietary supplements, pharma, and agriculture markets since 1872. Sacco System is one of the largest contract fermentation organizations in the world.

As an official technology partner to Sacco System, CSL USA enters the US market with a strong platform of science and a long history of fermentation experience. CSL USA will promote the full line of food ingredients, food cultures, bacterial cultures, probiotics, and comprehensive fermentation services to customers in the US.

CSL USA will accelerate efforts to serve both the health and nutrition and the food and beverage markets globally as we bring new products and service to the US marketplace.



***Lactaseibacillus rhamnosus* CA15, a promising new Women's Health probiotic strain**

Abstract

Lactaseibacillus rhamnosus CA15 is a new promising probiotic strain for women's health targeting vaginal tract diseases. Its vaginal health effects, including a reduction in the recurrence of both bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC), are well documented. The strain has been extensively studied for its functional properties, including its genomic and surface properties, its ability to inhibit adhesion and biofilm formation of urogenital-associated pathogens in women. The daily intake of CA15 strain for 10 days to treat BV and VVC was investigated and showed a significant reduction of Candida, Gardnerella and other pathogens burden, improved symptoms, and resolution of the vaginal infections.

Key Elements

- CA15 strain shown to reach the vagina following oral route
- CA15 strain inhibits adhesion and biofilm formation of urogenital-associated pathogens
- The daily intake of CA15 strain for 10 days improves vaginal dysbiosis symptoms, resulting in a restoration of indigenous lactobacilli even 30 days after stopping oral administration